Equities

STRATA Skin Sciences Inc

STRATA Skin Sciences Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.09
  • Today's Change-0.078 / -2.47%
  • Shares traded435.00
  • 1 Year change-66.04%
  • Beta1.4205
Data delayed at least 15 minutes, as of Jul 05 2024 16:37 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.

  • Revenue in USD (TTM)32.55m
  • Net income in USD-11.36m
  • Incorporated1997
  • Employees99.00
  • Location
    STRATA Skin Sciences Inc5 Walnut Grove Dr Ste 140HORSHAM 19044-2252United StatesUSA
  • Phone+1 (215) 619-3200
  • Fax+1 (215) 619-3209
  • Websitehttp://www.strataskinsciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PAVmed Inc3.02m-71.05m6.68m107.00------2.21-9.08-9.080.3874-7.760.0588--64.1728,186.92-147.38-154.56---1,152.82-126.09---2,505.37-8,764.890.5301-8.321.82--550.40--25.76--55.51--
Golden Valley Development Inc0.00-92.53k6.84m0.00---------11.17-11.170.00-0.02110.00-------7,710.83-------------3,073.27---3.96--------45.48------
Biomerica Inc5.41m-6.35m7.33m62.00--0.9393--1.36-0.3789-0.37890.32240.46420.58272.285.7487,180.80-68.45-43.55-83.73-50.3211.4115.75-117.46-55.863.37--0.00---71.71-0.8229-57.58---9.76--
Fuse Medical Inc18.40m3.63m7.38m31.002.78--2.000.40110.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Vivos Therapeutics Inc13.36m-15.64m7.42m114.00--10.79--0.5555-11.00-11.008.730.21310.9247--31.59117,219.30-108.24-89.72-243.30-149.7058.9070.20-117.06-113.15----0.00---13.8729.4843.04---8.48--
Neurometrix Inc5.27m-7.98m7.44m26.00--0.392--1.41-6.32-6.324.209.440.23811.2510.08202,700.40-36.07-23.24-38.94-27.2661.9759.17-151.51-48.8810.11--0.00---28.52-18.18-47.84--5.03--
Precipio Inc15.81m-4.90m7.50m51.00--0.5713--0.4742-3.73-3.7311.608.930.877317.8517.93310,039.20-27.20-44.98-34.82-58.6839.1428.80-31.00-118.070.6201-350.950.0278--61.4639.6252.04--5.37--
Guided Therapeutics Inc82.00k-3.23m8.01m4.00------97.72-0.0623-0.06230.0016-0.07210.03740.090411.7120,500.00-137.80-136.13----32.9329.39-3,685.37-3,666.670.1138-11.13----653.8511.4524.40------
PetVivo Holdings Inc1.05m-10.63m9.16m25.00--7.67--8.75-0.8694-0.86940.08420.060.33751.212.0441,841.60-343.12-209.90-715.73-504.6451.4120.27-1,016.55-2,297.210.6169-2,268.840.1392--693.46260.32-73.83--51.73--
Innovative Eyewear Inc1.39m-7.20m9.82m11.00--1.42--7.06-0.6074-0.60740.11740.29480.28031.8915.42126,457.30-145.15---168.75---8.82---517.88--3.68-6,764.710.00--74.67---17.28------
STRATA Skin Sciences Inc32.55m-11.36m10.83m99.00--1.15--0.3329-3.25-3.259.312.690.733.678.60328,737.40-25.49-11.48-35.77-16.5552.7161.28-34.91-17.700.8376-3.900.6151---7.752.24-95.17--23.29--
Autonomix Medical Inc0.00-15.43m12.06m5.00--1.58-----0.7614-0.76140.000.4048------0.00--------------------0.1161-------674.99------
Vapotherm Inc70.07m-54.94m12.74m182.00------0.1818-8.62-8.6211.00-11.020.81221.467.53385,011.00-63.68-49.73-587.27-62.5445.2843.56-78.40-78.990.1259-1.272.59--2.8010.1448.62---10.38--
Scientific Industries Inc10.79m-8.77m13.65m63.00--1.08--1.27-1.13-1.131.341.200.67621.199.31171,263.50-54.96---63.27--44.53---81.28--3.19--0.00--------------
Nexalin Technology Inc158.86k-4.94m13.66m6.00--4.12--85.97-0.6676-0.66760.02150.31290.03630.177844.0126,476.67-112.76---139.94--82.54---3,110.58--4.75--0.00---91.62---173.80------
QT Imaging Holdings Inc0.00-4.02m15.24m----0.7008-----0.3999-0.39990.001.010.00-------12.32---16.60--------------0.3042-------45.07------
Data as of Jul 05 2024. Currency figures normalised to STRATA Skin Sciences Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.